Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interleukin-15 to Promote Post-ART Control of HIV
NCT07145164Phase 2Enrolling by invitation
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing N-803 with Placebo (2 arms). Primary endpoints: Safety - Solicited Adverse Events at 7 days and Safety - Unsolicited Adverse Events at 7 days. Started Aug 2025; status: enrolling by invitation.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07145164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145164.